Silvana Novelli
@snovelli.bsky.social
Hematologist. #Lymphoma #immunotherapy #ITP 🏥 Institut Català d’Oncologia- Barcelona. Tap dancer 🎼
Now it is imperative to include CLIPI in the routine evaluation of advanced stages Mycosis Fungoides & Sézary syndrome; especially when considering for alloSCT #ctcl
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
Key PointsThere is poor survival in advanced stage MF/SS.CLIPI stratifies patients with advanced MF/SS into risk groups for survival and has been validated
ashpublications.org
October 29, 2025 at 7:14 PM
Now it is imperative to include CLIPI in the routine evaluation of advanced stages Mycosis Fungoides & Sézary syndrome; especially when considering for alloSCT #ctcl
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Silvana Novelli
Reviewing this classic article @bmj.com
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
doi.org/10.1136/bmj....
I still teach it all the time
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
doi.org/10.1136/bmj....
I still teach it all the time
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
In this article by Robert Yeh and colleagues ( BMJ 2018;363:k5094, doi:10.1136/bmj.k5094), the final sentence of the Methods section should …
doi.org
October 21, 2025 at 5:45 PM
Reviewing this classic article @bmj.com
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
doi.org/10.1136/bmj....
I still teach it all the time
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
doi.org/10.1136/bmj....
I still teach it all the time
Reposted by Silvana Novelli
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
October 18, 2025 at 12:57 PM
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
Lo mejor de escuchar a otros especialistas es cuando te encuentras con inmunólogas como la Dra. Silvia Vidal y te da una clase de #XPO #selinexor en el #mieloma
#Hemato2025 @sehhematologia.bsky.social
#Hemato2025 @sehhematologia.bsky.social
October 11, 2025 at 12:46 PM
Lo mejor de escuchar a otros especialistas es cuando te encuentras con inmunólogas como la Dra. Silvia Vidal y te da una clase de #XPO #selinexor en el #mieloma
#Hemato2025 @sehhematologia.bsky.social
#Hemato2025 @sehhematologia.bsky.social
“Manejo periquirúrgico de los pacientes con coagulopatías adquiridas inmunológicas” con Eva Mingot, un enfoque práctico. @hospitaluvrocio.bsky.social @sehhematologia.bsky.social #Hemato2025
October 11, 2025 at 7:50 AM
“Manejo periquirúrgico de los pacientes con coagulopatías adquiridas inmunológicas” con Eva Mingot, un enfoque práctico. @hospitaluvrocio.bsky.social @sehhematologia.bsky.social #Hemato2025
“Perfil molecular en la leucemia linfática crónica: más allá del TP53”. @ferrannadeu.bsky.social nos revela el universo de complejidad biológica de la #LLC @idibaps.bsky.social @sehhematologia.bsky.social #Hemato2025
October 11, 2025 at 7:05 AM
“Perfil molecular en la leucemia linfática crónica: más allá del TP53”. @ferrannadeu.bsky.social nos revela el universo de complejidad biológica de la #LLC @idibaps.bsky.social @sehhematologia.bsky.social #Hemato2025
Rafael de la Cámara nos revela la inmensa cantidad de fármacos antivirales en ensayo para mejorar el cuidado de nuestros pacientes. @sehhematologia.bsky.social #Hemato2025
October 11, 2025 at 6:55 AM
Rafael de la Cámara nos revela la inmensa cantidad de fármacos antivirales en ensayo para mejorar el cuidado de nuestros pacientes. @sehhematologia.bsky.social #Hemato2025
CART de la Mano de Dr. Olalekan O. Oluwole - #Kite #hemato2025 @sehhematologia.bsky.social
October 9, 2025 at 12:39 PM
CART de la Mano de Dr. Olalekan O. Oluwole - #Kite #hemato2025 @sehhematologia.bsky.social
Secuenciación de tercera generación en el diagnóstico hematológico. Dr. Javier Corral de la Calle repasando la evolución de la NGS. #hemato2025 @sehhematologia.bsky.social
October 9, 2025 at 8:38 AM
Secuenciación de tercera generación en el diagnóstico hematológico. Dr. Javier Corral de la Calle repasando la evolución de la NGS. #hemato2025 @sehhematologia.bsky.social
Platelet transcriptomic-powered scientific discovery in Thrombosis and Hemostasis Dr. Matthew T. Rondina
Huntsman Cancer Institute & University of Utah Health,
Salt Lake City, Utah (USA). #sepsis #inflamación #hemato2025 ❤️
Huntsman Cancer Institute & University of Utah Health,
Salt Lake City, Utah (USA). #sepsis #inflamación #hemato2025 ❤️
October 9, 2025 at 7:51 AM
Platelet transcriptomic-powered scientific discovery in Thrombosis and Hemostasis Dr. Matthew T. Rondina
Huntsman Cancer Institute & University of Utah Health,
Salt Lake City, Utah (USA). #sepsis #inflamación #hemato2025 ❤️
Huntsman Cancer Institute & University of Utah Health,
Salt Lake City, Utah (USA). #sepsis #inflamación #hemato2025 ❤️
“Selection of best donor in allogeneic stem cell transplantation: beyond HLA typing” por la Dra. Effie Wang Petersdorf #hemato2025 #educacional @sehhematologia.bsky.social
October 9, 2025 at 6:45 AM
“Selection of best donor in allogeneic stem cell transplantation: beyond HLA typing” por la Dra. Effie Wang Petersdorf #hemato2025 #educacional @sehhematologia.bsky.social
Es un lujo poder escuchar al Dr. Orfao hablando de la EMR en ls distintas neoplasias hematológicas #Hemato2025 @sehhematologia.bsky.social
October 9, 2025 at 6:27 AM
Es un lujo poder escuchar al Dr. Orfao hablando de la EMR en ls distintas neoplasias hematológicas #Hemato2025 @sehhematologia.bsky.social
Administration of SUMOylation inhibitor could eradicate #Burkitt’s #lymphoma treated with CD19 CAR-T.
rdcu.be/eJu9C
rdcu.be/eJu9C
Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy
Signal Transduction and Targeted Therapy - Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy
rdcu.be
October 4, 2025 at 9:03 PM
Administration of SUMOylation inhibitor could eradicate #Burkitt’s #lymphoma treated with CD19 CAR-T.
rdcu.be/eJu9C
rdcu.be/eJu9C
What a beautiful work from our colleagues from Navarra! @unav.edu #CUN
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality #MM
ashpublications.org/blood/articl...
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality #MM
ashpublications.org/blood/articl...
Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma
Key Points. Glutamine deprivation in the tumor microenvironment might limit CAR T-cell therapeutic efficacy in cancer patients.ASCT2 overexpression improve
ashpublications.org
September 21, 2025 at 8:23 PM
What a beautiful work from our colleagues from Navarra! @unav.edu #CUN
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality #MM
ashpublications.org/blood/articl...
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality #MM
ashpublications.org/blood/articl...
Improved PFS with Moga-Chop for elderly ATL patients. I wonder how the Moga
-Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
-Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma
Key PointsMoga-CHOP significantly improved 1-year PFS in older patients with aggressive ATL.CCR4 mutations and Moga-associated cAEs were related to better
ashpublications.org
September 21, 2025 at 8:10 PM
Improved PFS with Moga-Chop for elderly ATL patients. I wonder how the Moga
-Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
-Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
Reposted by Silvana Novelli
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
September 15, 2025 at 2:36 PM
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
Reposted by Silvana Novelli
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
ashpublications.org
September 9, 2025 at 8:34 PM
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...
Reposted by Silvana Novelli
Addition of lisaftoclax to myeloma regimens improved depth of response
sohoinsider.com/meetings-con...
sohoinsider.com/meetings-con...
lisaftoclax boosts response in mm, amyloidosis - SOHO Insider
Phase 1b/2 study shows lisaftoclax with Pd or DRd yields 61.3% ORR in relapsed MM, AL amyloidosis at SOHO 2025
sohoinsider.com
September 8, 2025 at 11:49 PM
Addition of lisaftoclax to myeloma regimens improved depth of response
sohoinsider.com/meetings-con...
sohoinsider.com/meetings-con...
Devimistat shows potential for a subset of BL patients, efforts should focus on improving initial therapies and exploring novel treatments for these challenging malignancies: ashpublications.org/bloodadvance...
Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial
Key Points. A targeted approach to block enzymes in the TCA cycle had limited efficacy in the treatment of patients with relapsed Burkitt lymphoma.The uniq
ashpublications.org
September 8, 2025 at 9:07 AM
Devimistat shows potential for a subset of BL patients, efforts should focus on improving initial therapies and exploring novel treatments for these challenging malignancies: ashpublications.org/bloodadvance...
Reposted by Silvana Novelli
Fraud, using A.I., impersonating medical professionals
Front page NY Times
www.nytimes.com/2025/09/05/t...
Front page NY Times
www.nytimes.com/2025/09/05/t...
September 7, 2025 at 2:04 PM
Fraud, using A.I., impersonating medical professionals
Front page NY Times
www.nytimes.com/2025/09/05/t...
Front page NY Times
www.nytimes.com/2025/09/05/t...
Reposted by Silvana Novelli
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL @societyofhemonc.bsky.social @brownmedicine.bsky.social #SOHO2025 #lymsm www.onclive.com/view/mosunet...
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL
A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.
www.onclive.com
September 6, 2025 at 5:29 PM
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL @societyofhemonc.bsky.social @brownmedicine.bsky.social #SOHO2025 #lymsm www.onclive.com/view/mosunet...
Reposted by Silvana Novelli
PS: I wrote about marimo in a larger feature on how to pick a programming language @nature.com: www.nature.com/articles/d41...
Which programming language should I use? A guide for early-career researchers
Computer scientists and bioinformaticians address four key questions to help rookie coders to make the right choice.
www.nature.com
August 27, 2025 at 4:53 PM
PS: I wrote about marimo in a larger feature on how to pick a programming language @nature.com: www.nature.com/articles/d41...
First-ever comparison between haplo-HSCT using modified post-transplantation cyclophosphamide and combined IST+EPAG.
www.astctjournal.org/article/S266...
www.astctjournal.org/article/S266...
Comparison of haploidentical-hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide and eltrombopag combined with immunosuppression for the treatment of severe ap...
Severe aplastic anemia (SAA) is a life-threatening disease mainly caused by abnormal
immune function in the form of T lymphocyte hyperfunction 1. SAA and very SAA (VSAA)
can be treated with human leuk...
www.astctjournal.org
August 9, 2025 at 7:43 PM
First-ever comparison between haplo-HSCT using modified post-transplantation cyclophosphamide and combined IST+EPAG.
www.astctjournal.org/article/S266...
www.astctjournal.org/article/S266...